Virtue Diagnostics Targets Southeast Asian Market
PT Virtue Diagnostics Indonesia is strengthening its commitment to developing an In Vitro Diagnostics (IVD) manufacturing ecosystem in Indonesia. The move is being pursued through increased investment, development of new product lines, and expansion of export markets amid challenges facing the national medical device industry.
The commitment was conveyed during a series of Industrial Symposiums at the INDOHEALTHCARE GAKESLAB Expo 2026. The forum served as a momentum for the company to demonstrate the synergy between global investment and local manufacturing capability in supporting the resilience of the national health system.
“Indonesia is a country with very unique geographical challenges. Thousands of islands, a large population, and still limited access to diagnostic services in various regions require solutions that are not only innovative but also locally produced. That is why we chose to build manufacturing in Indonesia, not merely sell products to Indonesia,” said Johnson Zhang.
Embracing the philosophy of “In the Region, for the Region”, Virtue Diagnostics has built a 12,200 square metre manufacturing facility in Cikarang. The facility, inaugurated in 2024, has a production capacity of more than 1,000 diagnostic instrument units per year and 6,000 litres of reagent per day.
In 2026, the company is increasing its investment in Indonesia by developing a molecular diagnostics line and launching cartridge-based immunology technology. The development complements the company’s existing product portfolio while expanding its ecosystem of diagnostic solutions.
To date, Virtue Diagnostics has obtained marketing authorisation for 193 diagnostic products in Indonesia. The company’s platforms, which cover immunology, biochemistry, haematology, and molecular diagnostics, have also achieved a Domestic Component Level (TKDN) of more than 40%.
These products are directed towards supporting a number of government priority programmes, including the Free Health Check-up Programme (CKG), tuberculosis elimination by 2030, and the cervical cancer screening programme through HPV testing.
Johnson said investment in the high-technology diagnostic manufacturing sector is a long-term investment. Therefore, he said, industry development requires an ecosystem that provides certainty for business players.
“We believe Indonesia has great potential to become an IVD manufacturing hub in the Southeast Asian region. To realise this, synergy is needed between the government and industry through policies that support long-term investment, value-based procurement, protection for products with high TKDN, multi-year procurement contracts, and closer communication before the implementation of new policies,” he said.
Associate Commercial Director of PT Virtue Diagnostics Indonesia, Kurniasari Endah, said the company has faced a number of challenges since entering the Indonesian market in 2024. Global economic conditions, changing market dynamics, and a decline in government spending on medical devices have put pressure on the national IVD industry.
Beyond market challenges, the company also had to build trust in local IVD products amid competition with global brands that have long been present in Indonesia.
“We realise that entering the Indonesian market in 2024 was not an easy journey. Besides facing challenging market conditions, we also had to build trust in local IVD products amid the dominance of global brands that have been present for decades,” said Kurniasari.
Facing these conditions, Virtue Diagnostics is not relying on a single market segment. The company is strengthening its penetration into the private sector, including hospitals, clinical laboratories, and other healthcare facilities.
The strategy is built on product quality, continuous innovation, and after-sales service, which are considered important factors in building customer trust.
The market strengthening strategy is beginning to show results. By mid-2026, PT Virtue Diagnostics Indonesia had produced more than 150 diagnostic instrument units and 31,000 reagent kits.
These products have been used in various hospitals and laboratories across Indonesia.
“This achievement is proof that IVD products manufactured in Indonesia are able to compete in terms of quality, performance, and reliability. We are proud that more healthcare professionals are entrusting their diagnostic services to domestically produced products,” said Kurniasari.
In terms of quality, the company has also obtained ISO 13485 certification, the international standard for Medical Device Quality Management Systems. The certification covers the development, production, and quality control processes to ensure products meet international standards.
In addition to strengthening the domestic market, Virtue Diagnostics is beginning to develop international markets. The company has exported VIRTUEDX-branded reagents and VERCENTRA diagnostic instruments to the Philippines.
The expansion is part of the company’s efforts to broaden its market while demonstrating the competitiveness of diagnostic products manufactured in Indonesia.
Going forward, Virtue Diagnostics plans to continue increasing investment in research and development, add manufacturing capacity, introduce diagnostic innovations, and expand its distribution network domestically and internationally.
Virtue Diagnostics believes that strengthening the IVD industry requires collaboration between the government, industry, healthcare professionals, academics, and other stakeholders. The combination of global investment, local manufacturing capability, technological innovation, and Indonesian human resources is seen as a foundation for the development of the national diagnostics industry.
Source: jawawa.id (https://jawawa.id/newsitem/virtue-diagnostics-targets-southeast-asian-market-1786110615)
Originally published by olenka.id (https://olenka.id/virtue-diagnostic-bidik-pasar-asia-tenggara/amp), translated from Indonesian